<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38965890</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Attenuated replication and damaging effects of SARS-CoV-2 Omicron variants in an intestinal epithelial barrier model.</ArticleTitle><Pagination><StartPage>e29783</StartPage><MedlinePgn>e29783</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29783</ELocationID><Abstract><AbstractText>Many COVID-19 patients suffer from gastrointestinal symptoms and impaired intestinal barrier function is thought to play a key role in Long COVID. Despite its importance, the impact of&#xa0;severe acute respiratory syndrome coronavirus 2&#xa0;(SARS-CoV-2) on intestinal epithelia is poorly understood. To address this, we established an intestinal barrier model integrating epithelial Caco-2 cells, mucus-secreting HT29 cells and Raji cells. This gut epithelial model allows efficient differentiation of Caco-2 cells into microfold-like cells, faithfully mimics intestinal barrier function, and is highly permissive to SARS-CoV-2 infection. Early strains of SARS-CoV-2 and the Delta variant replicated with high efficiency, severely disrupted barrier function, and depleted tight junction proteins, such as claudin-1, occludin, and ZO-1. In comparison, Omicron subvariants also depleted ZO-1 from tight junctions but had fewer damaging effects on mucosal integrity and barrier function. Remdesivir, the fusion inhibitor EK1 and the transmembrane serine protease 2 inhibitor Camostat inhibited SARS-CoV-2 replication and thus epithelial barrier damage, while the Cathepsin inhibitor E64d was ineffective. Our results support that SARS-CoV-2 disrupts intestinal barrier function but further suggest that circulating Omicron variants are less damaging than earlier viral strains.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volcic</LastName><ForeName>Meta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6406-7683</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nchioua</LastName><ForeName>Rayhane</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastorio</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zech</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hau&#xdf;mann</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauter</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Read</LastName><ForeName>Clarissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Central Facility for Electron Microscopy, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walther</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Central Facility for Electron Microscopy, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7052-2360</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>SA 2676/3-1</Agency><Country/></Grant><Grant><Agency>Deutsche Forschungsgemeinschaft (DFG) under CRC1279</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062826">Zonula Occludens-1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062793">Occludin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569042">TJP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="Y">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019108" MajorTopicYN="Y">Tight Junctions</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062826" MajorTopicYN="N">Zonula Occludens-1 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062793" MajorTopicYN="N">Occludin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">gut barrier</Keyword><Keyword MajorTopicYN="N">intestinal epithelium model</Keyword><Keyword MajorTopicYN="N">tight junctions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>3</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38965890</ArticleId><ArticleId IdType="doi">10.1002/jmv.29783</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ahn JH, Kim J, Hong SP, et al. Nasal ciliated cells are primary targets for SARS&#x2010;CoV&#x2010;2 replication in the early stage of COVID&#x2010;19. J Clin Invest. 2021;131(13):e148517. doi:10.1172/JCI148517</Citation></Reference><Reference><Citation>Lamers MM, Haagmans BL. SARS&#x2010;CoV&#x2010;2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270&#x2010;284. doi:10.1038/s41579-022-00713-0</Citation></Reference><Reference><Citation>Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ&#x2010;specific manifestations of COVID&#x2010;19 infection. Clin Exp Med. 2020;20(4):493&#x2010;506. doi:10.1007/s10238-020-00648-x</Citation></Reference><Reference><Citation>Zhong P, Xu J, Yang D, et al. COVID&#x2010;19&#x2010;associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. 2020;5(1):256. doi:10.1038/s41392-020-00373-7</Citation></Reference><Reference><Citation>Hayashi Y, Wagatsuma K, Nojima M, et al. The characteristics of gastrointestinal symptoms in patients with severe COVID&#x2010;19: a systematic review and meta&#x2010;analysis. J Gastroenterol. 2021;56(5):409&#x2010;420. doi:10.1007/s00535-021-01778-z</Citation></Reference><Reference><Citation>Cappell MS, Friedel DM. Gastrointestinal bleeding in COVID&#x2010;19&#x2010;infected patients. Gastroenterol Clin North Am. 2023;52(1):77&#x2010;102. doi:10.1016/j.gtc.2022.10.004</Citation></Reference><Reference><Citation>Eleftheriotis G, Tsounis EP, Aggeletopoulou I, et al. Alterations in gut immunological barrier in SARS&#x2010;CoV&#x2010;2 infection and their prognostic potential. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1129190</Citation></Reference><Reference><Citation>Assimakopoulos SF, Eleftheriotis G, Lagadinou M, et al. SARS CoV&#x2010;2&#x2010;Induced viral sepsis: the role of gut barrier dysfunction. Microorganisms. 2022;10(5):1050. doi:10.3390/microorganisms10051050</Citation></Reference><Reference><Citation>Zhang J, Garrett S, Sun J. Gastrointestinal symptoms, pathophysiology, and treatment in COVID&#x2010;19. Gene Dis. 2021;8(4):385&#x2010;400. doi:10.1016/j.gendis.2020.08.013</Citation></Reference><Reference><Citation>Jin B, Singh R, Ha SE, Zogg H, Park PJ, Ro S. Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID&#x2010;19. World J Gastroenterol. 2021;27(19):2341&#x2010;2352. doi:10.3748/wjg.v27.i19.2341</Citation></Reference><Reference><Citation>Scaldaferri F, Ianiro G, Privitera G, et al. The thrilling journey of SARS&#x2010;CoV&#x2010;2 into the intestine: from pathogenesis to future clinical implications. Inflamm Bowel Dis. 2020;26(9):1306&#x2010;1314. doi:10.1093/ibd/izaa181</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al&#x2010;Aly Z. Long&#x2010;term gastrointestinal outcomes of COVID&#x2010;19. Nat Commun. 2023;14(1):983. doi:10.1038/s41467-023-36223-7</Citation></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Schroeder S, et al. SARS&#x2010;CoV&#x2010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2010;280.e8. doi:10.1016/j.cell.2020.02.052</Citation></Reference><Reference><Citation>Guimar&#xe3;es Sousa S, Kleiton de Sousa A, Maria Carvalho Pereira C, et al. SARS&#x2010;CoV&#x2010;2 infection causes intestinal cell damage: role of interferon's imbalance. Cytokine. 2022;152:155826. doi:10.1016/j.cyto.2022.155826</Citation></Reference><Reference><Citation>Rahban M, Stanek A, Hooshmand A, et al. Infection of human cells by SARS&#x2010;CoV&#x2010;2 and molecular overview of gastrointestinal, neurological, and hepatic problems in COVID&#x2010;19 patients. J Clin Med. 2021;10(21):4802. doi:10.3390/jcm10214802</Citation></Reference><Reference><Citation>Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID&#x2010;19. Trans R Soc Trop Med Hyg. 2021;115(12):1362&#x2010;1388. doi:10.1093/trstmh/trab042</Citation></Reference><Reference><Citation>Jiao L, Li H, Xu J, et al. The gastrointestinal tract is an alternative route for SARS&#x2010;CoV&#x2010;2 infection in a nonhuman primate model. Gastroenterology. 2021;160(5):1647&#x2010;1661. doi:10.1053/j.gastro.2020.12.001</Citation></Reference><Reference><Citation>Neuberger M, Jungbluth A, Irlbeck M, et al. Duodenal tropism of SARS&#x2010;CoV&#x2010;2 and clinical findings in critically ill COVID&#x2010;19 patients. Infection. 2022;50(5):1111&#x2010;1120. doi:10.1007/s15010-022-01769-z</Citation></Reference><Reference><Citation>Yamada S, Noda T, Okabe K, Yanagida S, Nishida M, Kanda Y. SARS&#x2010;CoV&#x2010;2 induces barrier damage and inflammatory responses in the human iPSC&#x2010;derived intestinal epithelium. J Pharmacol Sci. 2022;149(3):139&#x2010;146. doi:10.1016/j.jphs.2022.04.010</Citation></Reference><Reference><Citation>Tsounis EP, Triantos C, Konstantakis C, Marangos M, Assimakopoulos SF. Intestinal barrier dysfunction as a key driver of severe COVID&#x2010;19. World J Virol. 2023;12(2):68&#x2010;90. doi:10.5501/wjv.v12.i2.68</Citation></Reference><Reference><Citation>Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID&#x2010;19 during time of hospitalization. Gastroenterology. 2020;159(3):944&#x2010;955.e8. doi:10.1053/j.gastro.2020.05.048</Citation></Reference><Reference><Citation>B&#xe9;duneau A, Tempesta C, Fimbel S, et al. A tunable Caco&#x2010;2/HT29&#x2010;MTX co&#x2010;culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. Eur J Pharmaceut Biopharmaceut. 2014;87(2):290&#x2010;298. doi:10.1016/j.ejpb.2014.03.017</Citation></Reference><Reference><Citation>Mahler GJ, Shuler ML, Glahn RP. Characterization of Caco&#x2010;2 and HT29&#x2010;MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability. J Nutr Biochem. 2009;20(7):494&#x2010;502. doi:10.1016/j.jnutbio.2008.05.006</Citation></Reference><Reference><Citation>Nchioua R, Schundner A, Klute S, et al. Reduced replication but increased interferon resistance of SARS&#x2010;CoV&#x2010;2 omicron BA.1. Life Science Alliance. 2023;6(6):e202201745. doi:10.26508/lsa.202201745</Citation></Reference><Reference><Citation>Sch&#xfc;tz D, Rode S, Read C, et al. Viral transduction enhancing effect of EF&#x2010;C peptide nanofibrils is mediated by cellular protrusions. Adv Funct Mater. 2021;31(40):2104814. doi:10.1002/adfm.202104814</Citation></Reference><Reference><Citation>Kremer JR, Mastronarde DN, McIntosh JR. Computer visualization of three&#x2010;dimensional image data using IMOD. J Struct Biol. 1996;116(1):71&#x2010;76. doi:10.1006/jsbi.1996.0013</Citation></Reference><Reference><Citation>Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12(5):319&#x2010;330. doi:10.1007/s11894-010-0131-2</Citation></Reference><Reference><Citation>Gagnon M, Zihler Berner A, Chervet N, Chassard C, Lacroix C. Comparison of the Caco&#x2010;2, HT&#x2010;29 and the mucus&#x2010;secreting HT29&#x2010;MTX intestinal cell models to investigate Salmonella adhesion and invasion. J Microbiol Meth. 2013;94(3):274&#x2010;279. doi:10.1016/j.mimet.2013.06.027</Citation></Reference><Reference><Citation>Perrotta F, Matera MG, Cazzola M, Bianco A. Severe respiratory SARS&#x2010;CoV2 infection: does ACE2 receptor matter? Respir Med. 2020;168:105996. doi:10.1016/j.rmed.2020.105996</Citation></Reference><Reference><Citation>Lee IT, Nakayama T, Wu CT, et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun. 2020;11(1):5453. doi:10.1038/s41467-020-19145-6</Citation></Reference><Reference><Citation>Cabellos J, Delpivo C, Fern&#xe1;ndez&#x2010;Rosas E, V&#xe1;zquez&#x2010;Campos S, Janer G. Contribution of M&#x2010;cells and other experimental variables in the translocation of TiO2 nanoparticles across in vitro intestinal models. NanoImpact. 2017;5:51&#x2010;60. doi:10.1016/j.impact.2016.12.005</Citation></Reference><Reference><Citation>Guo M, Tao W, Flavell RA, Zhu S. Potential intestinal infection and faecal&#x2013;oral transmission of SARS&#x2010;CoV&#x2010;2. Nat Rev Gastroenterol Hepatol. 2021;18(4):269&#x2010;283. doi:10.1038/s41575-021-00416-6</Citation></Reference><Reference><Citation>Clerbaux LA, Mayasich SA, Mu&#xf1;oz A, et al. Gut as an alternative entry route for SARS&#x2010;CoV&#x2010;2: current evidence and uncertainties of productive enteric infection in COVID&#x2010;19. J Clin Med. 2022;11(19):5691. doi:10.3390/jcm11195691</Citation></Reference><Reference><Citation>Hoffmann M, Hofmann&#x2010;Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS&#x2010;CoV&#x2010;2 activation by TMPRSS2&#x2010;related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021;65:103255. doi:10.1016/j.ebiom.2021.103255</Citation></Reference><Reference><Citation>Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS&#x2010;CoV&#x2010;2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):134. doi:10.1038/s41392-021-00558-8</Citation></Reference><Reference><Citation>Xia S, Chan JFW, Wang L, et al. Peptide&#x2010;based pan&#x2010;CoV fusion inhibitors maintain high potency against SARS&#x2010;CoV&#x2010;2 Omicron variant. Cell Res. 2022;32(4):404&#x2010;406. doi:10.1038/s41422-022-00617-x</Citation></Reference><Reference><Citation>Xia S, Lan Q, Zhu Y, et al. Structural and functional basis for pan&#x2010;CoV fusion inhibitors against SARS&#x2010;CoV&#x2010;2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021;6(1):288. doi:10.1038/s41392-021-00712-2</Citation></Reference><Reference><Citation>Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct&#x2010;acting antiviral that inhibits RNA&#x2010;dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785&#x2010;6797. doi:10.1074/jbc.RA120.013679</Citation></Reference><Reference><Citation>Kuo WT, Zuo L, Odenwald MA, et al. The tight junction protein ZO&#x2010;1 is dispensable for barrier function but critical for effective mucosal repair. Gastroenterology. 2021;161(6):1924&#x2010;1939. doi:10.1053/j.gastro.2021.08.047</Citation></Reference><Reference><Citation>Song Z, Bao L, Yu P, et al. SARS&#x2010;CoV&#x2010;2 causes a systemically multiple organs damages and dissemination in hamsters. Front Microbiol. 2021;11. doi:10.3389/fmicb.2020.618891</Citation></Reference><Reference><Citation>Frappart PO, Walter K, Gout J, et al. Pancreatic cancer&#x2010;derived organoids&#x2014;a disease modeling tool to predict drug response. United European Gastroenterol J. 2020;8(5):594&#x2010;606. doi:10.1177/2050640620905183</Citation></Reference><Reference><Citation>Han Y, Yang L, Lacko LA, Chen S. Human organoid models to study SARS&#x2010;CoV&#x2010;2 infection. Nat Meth. 2022;19(4):418&#x2010;428. doi:10.1038/s41592-022-01453-y</Citation></Reference><Reference><Citation>Kr&#xfc;ger J, Gro&#xdf; R, Conzelmann C. Drug Inhibition of SARS&#x2010;CoV&#x2010;2 Replication in Human Pluripotent Stem Cell&#x2010;Derived Intestinal Organoids. Cell Mol Gastroenterol Hepatol. 2020;11(4):935&#x2010;948. doi:10.1016/j.jcmgh.2020.11.003</Citation></Reference><Reference><Citation>Miyakawa K, Machida M, Kawasaki T, Nishi M, Akutsu H, Ryo A. Reduced replication efficacy of severe acute respiratory syndrome coronavirus 2 omicron variant in &#x201c;mini&#x2010;gut&#x201d; organoids. Gastroenterology. 2022;163(2):514&#x2010;516. doi:10.1053/j.gastro.2022.04.043</Citation></Reference><Reference><Citation>Khreefa Z, Barbier MT, Koksal AR, Love G, Del Valle L. Pathogenesis and mechanisms of SARS&#x2010;CoV&#x2010;2 infection in the intestine, liver, and pancreas. Cells. 2023;12(2):262. doi:10.3390/cells12020262</Citation></Reference><Reference><Citation>Jang KK, Kaczmarek ME, Dallari S, et al. Variable susceptibility of intestinal organoid&#x2013;derived monolayers to SARS&#x2010;CoV&#x2010;2 infection. PLoS Biol. 2022;20(3):e3001592. doi:10.1371/journal.pbio.3001592</Citation></Reference><Reference><Citation>Mabbott NA, Donaldson DS, Ohno H, Williams IR, Mahajan A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013;6(4):666&#x2010;677. doi:10.1038/mi.2013.30</Citation></Reference><Reference><Citation>Corr SC, Gahan CC, Hill C. M&#x2010;cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol. 2008;52(1):2&#x2010;12. doi:10.1111/j.1574-695X.2007.00359.x</Citation></Reference><Reference><Citation>Kimura S. Molecular insights into the mechanisms of M&#x2010;cell differentiation and transcytosis in the mucosa&#x2010;associated lymphoid tissues. Anat Sci Int. 2018;93(1):23&#x2010;34. doi:10.1007/s12565-017-0418-6</Citation></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS&#x2010;CoV&#x2010;2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. The Lancet. 2022;399(10335):1618&#x2010;1624. doi:10.1016/S0140-6736(22)00327-0</Citation></Reference><Reference><Citation>Shi Y, Simpson S, Chen Y, Aull H, Benjamin J, Serra&#x2010;Moreno R. Mutations accumulated in the spike of SARS&#x2010;CoV&#x2010;2 omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin. PLoS Pathog. 2024;20(1):e1011912. doi:10.1371/journal.ppat.1011912</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>